Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Canadian firm to make generic Ozempic post-2026 patent expiry; U.S. price talk spurs Novo Nordisk stock drop.
Canadian company Vimy Pharma plans to produce a generic version of Ozempic, containing semaglutide, to improve affordability and access in Canada, with domestic manufacturing set to begin after patent expiry in early 2026.
Meanwhile, Novo Nordisk shares dropped 5.6% to 7% on October 17, 2025, following former President Donald Trump’s announcement that U.S. prices for weight-loss drugs like Ozempic could be slashed to $150 per month, citing the “most favored nation” policy.
The remarks, made during a White House event, triggered investor concerns over regulatory pressure and pricing reforms, though no immediate policy changes were enacted.
In response, Novo Nordisk appointed Greg Miley, a former AbbVie executive with strong U.S. government affairs experience, as its new head of corporate affairs to navigate political scrutiny.
The company is also undergoing a major restructuring, including 9,000 job cuts.
The FDA launched a pilot program to accelerate reviews of nine high-priority drugs, including an infertility treatment, to address critical public health issues.
La empresa canadiense hará el genérico Ozempic después de la expiración de la patente en 2026; las conversaciones sobre los precios en los Estados Unidos impulsan la caída de las acciones de Novo Nordisk.